Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients
Crossref DOI link: https://doi.org/10.1007/s12032-017-0922-5
Published Online: 2017-03-22
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Osada, Yuki
Arakaki, Hideki
Takanashi, Satoshi
Ito, Chisako
Aisa, Yoshinobu
Nakazato, Tomonori
License valid from 2017-03-22